New CEO Maria Halasz Brings 20+ Years’ Experience to Genetic Signatures

Leadership Change at Genetic Signatures

Genetic Signatures Limited (ASX – GSS), a specialist in molecular diagnostics, has announced the appointment of Maria Halasz as its new Chief Executive Officer, effective 2 March 2026. Ms Halasz steps into the role with a formidable track record spanning over 20 years in senior executive positions, particularly within life sciences and healthcare sectors.

Her expertise lies in commercialisation, corporate strategy, and investor engagement, areas critical to Genetic Signatures as it seeks to expand its global presence. The company’s patented 3base® technology, which simplifies pathogen identification, has positioned it well in the molecular diagnostics market, and Ms Halasz’s leadership is expected to accelerate this momentum.

A Proven Commercialisation Leader

Before joining Genetic Signatures, Ms Halasz served as CEO and Managing Director of Anagenics Limited (formerly Cellmid Limited) for 14 years, where she successfully led multiple capital raisings, asset acquisitions, and licensing deals. Her ability to engage with both institutional and retail investors will be invaluable as Genetic Signatures navigates its next growth phase.

Chair Caroline Waldron highlighted Ms Halasz’s rare combination of scientific understanding and capital markets credibility, noting that these qualities align perfectly with the company’s strategic ambitions. Ms Halasz herself expressed enthusiasm about scaling the business and expanding its international footprint, signalling a clear focus on translating innovation into tangible commercial success.

Remuneration and Future Leadership Moves

The terms of Ms Halasz’s employment include a base salary of A$400,000 per annum, complemented by a short-term incentive opportunity of up to 37.5% of base pay for stretch performance targets, and long-term performance rights potentially worth up to 80% of base salary. Notably, no short-term incentive will be paid for the current financial year, reflecting the timing of her appointment.

Meanwhile, Genetic Signatures is continuing its search for a permanent Chief Financial Officer, a key role that will support the company’s financial strategy as it pursues growth. The progress of this recruitment will be closely watched by investors eager to see a full executive team in place.

Looking Ahead

With Ms Halasz at the helm, Genetic Signatures is poised to leverage its innovative diagnostic platform and deepen its international market penetration. The company’s ability to convert scientific innovation into shareholder value will be a critical test of this leadership transition.